Apollon Formularies says medical cannabis formulations effective at killing breast cancer cells
Apollon Formularies PLC (LON:APOL) said a combined formulation of its medical cannabis treatment and medicinal mushrooms developed by Canadian firm Aion Therapeutic Inc have been effective at killing HER2+ breast cancer cells, the cause of around 20% of all breast cancers.
The pharmaceutical firm said testing by independent laboratory BIOENSIS had shown its medical cannabis formulations were “particularly effective” at killing living HER2+ cancer cells directly, while Aion’s medicinal mushroom formulations were most effective in stimulating the immune system’s T-cell production to attack and kill HER2+ cancer cells.
WATCH: Apollon Formularies’ Dr. Barnhill inspired by mums’ death to cure cancer nausea with THC led medication products
When the two formulations were combined, Apollon said nearly 100% of HER2+ cells in 3D cell cultures were killed.
Apollon’s cannabis formulation was developed by its affiliate, Apollon Formularies Jamaica, while the testing occurred as part of a joint testing agreement between the parties in accordance with a research & development licence issued by the Jamaican government’s Cannabis Licensing Authority.
“Cannabinoids have been seen to exert ‘antitumor’ effects by a number of different means, including killing cancer cells directly as well as inhibiting transformed cell growth and tumour metastasis. Apollon Jamaica, using results from its proprietary artificial intelligence based analysis on strain genetics, has cultivated and processed certain of its proprietary medical cannabis products with cancer treatment expressly in mind. We are excited that our formulations have been validated via independent laboratory testing to kill HER2+ breast cancer cells in 3D cell culture through direct cytotoxicity”, Apollon chief executive Stephen Barnhill said in a statement.
“It is our theory that use of a combination of anticancer therapies, especially ones involving separate treatment pathways, may have advantages over single-agent-based strategies as they may allow simultaneous or serial targeting of tumour growth, progression, and/or spreading at different levels with efforts to kill cancer cells”, he added.